Shanghai - Delayed Quote CNY

Kangmei Pharmaceutical Co., Ltd. (600518.SS)

1.9800
0.0000
(0.00%)
At close: 3:00:03 PM GMT+8
Loading Chart for 600518.SS
  • Previous Close 1.9800
  • Open 2.0000
  • Bid 1.9800 x --
  • Ask 1.9900 x --
  • Day's Range 1.9800 - 2.0100
  • 52 Week Range 1.6800 - 2.9500
  • Volume 132,286,701
  • Avg. Volume 198,249,420
  • Market Cap (intraday) 27.451B
  • Beta (5Y Monthly) 0.60
  • PE Ratio (TTM)
  • EPS (TTM) 0.0000
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date Aug 28, 2019
  • 1y Target Est --

Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese herbal medicines in China. The company offers Chinese patent medicines, chemical medicines, and health food products. In addition, it engages in the operation of Chinese medicinal materials markets; production and sale of medical devices; and operation of pharmaceutical logistics system. The company provides its products through medical institution resources, smart pharmacies, OTC retail, chain drug stores, direct sales, medical e-commerce, mobile medical care, etc. Kangmei Pharmaceutical Co., Ltd. was founded in 1997 and is based in Shenzhen, China.

www.kangmei.com.cn

4,409

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 600518.SS

View More

Performance Overview: 600518.SS

Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

600518.SS
15.38%
SSE Composite Index (000001.SS)
0.69%

1-Year Return

600518.SS
0.51%
SSE Composite Index (000001.SS)
7.21%

3-Year Return

600518.SS
23.55%
SSE Composite Index (000001.SS)
9.42%

5-Year Return

600518.SS
26.12%
SSE Composite Index (000001.SS)
16.45%

Compare To: 600518.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 600518.SS

View More

Valuation Measures

As of 5/12/2025
  • Market Cap

    27.45B

  • Enterprise Value

    26.70B

  • Trailing P/E

    3.30k

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.45

  • Price/Book (mrq)

    3.82

  • Enterprise Value/Revenue

    5.05

  • Enterprise Value/EBITDA

    462.46

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    4.90%

  • Return on Assets (ttm)

    1.21%

  • Return on Equity (ttm)

    3.71%

  • Revenue (ttm)

    5.21B

  • Net Income Avi to Common (ttm)

    255.55M

  • Diluted EPS (ttm)

    0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    773.59M

  • Total Debt/Equity (mrq)

    3.05%

  • Levered Free Cash Flow (ttm)

    -195.77M

Research Analysis: 600518.SS

View More

People Also Watch